Key Developments For Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. (CBLI.O) (Consolidated Issue listed on NASDAQ Capital Market)
Cleveland BioLabs, Inc. Publishes New Insights Into Mechanism Of Action Of Curaxins, Extending Their Clinical Potential
Cleveland BioLabs, Inc. announced that a breakthrough discovery into the mechanism of action of the Company's first generation Curaxin anticancer compounds was published in an international health science journal, Cell Cycle (Neznanov et al., Cell Cycle 8:23, 1-11; December 1, 2009). The published study examined the ability of the Company's prototype Curaxin (CBLC102, or quinacrine) to inhibit heat shock response, a major adaptive pro-survival pathway that rescues cells from stressful conditions involving accumulation of misfolded proteins (known as proteotoxic stress). Tumor cells typically become dependent on constitutive activity of this salvaging mechanism making them selectively susceptible to its inhibitors, especially if applied in combination with certain cancer therapies provoking proteotoxic stress.
Department of Defense Increases Ongoing Contract With Cleveland BioLabs, Inc. For Developmental Studies Related To Protectan
Cleveland BioLabs, Inc. announced that the Chemical Biological Medical Systems Medical Identification and Treatment Systems Joint Program Executive Office (CBMS-MITS JPEO) of The Department of Defense (DoD) increased the Company's ongoing contract, awarded in April 2008 for developmental studies related to Protectan CBLB502, from $8.86 million to $9.59 million.
Cleveland BioLabs, Inc. Receives $2.3 Million Addition to $13.3 Million Contract With Biomedical Advanced Research and Development Authority
Cleveland BioLabs, Inc. announced that the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (DHHS) exercised the first milestone-based option on the Company's existing contract under the Broad Agency Announcement titled, 'Therapies for Hematopoietic Syndrome, Bone Marrow Stromal Cell Loss, and Vascular Injury Resulting from Acute Exposure to Ionizing Radiation', for selected tasks in the advanced development of Protectan CBLB502. In addition, BARDA increased the first milestone-based option from $4.0 million to $6.3 million, increasing the total contract value including all milestone-based options from $13.3 million to $15.6 million over the three-year period.
Cleveland BioLabs, Inc. And Zhejiang Hisun Pharmaceutical Co. Ltd. Enter License Agreement For Protectan CBLB612 Hematopoietic Stem
Cleveland BioLabs, Inc. and Zhejiang Hisun Pharmaceutical Co. Ltd. , announced the execution of a license agreement granting Hisun exclusive rights to develop and commercialize Protectan CBLB612 in the People's Republic of China. Under the terms of the license agreement, Cleveland BioLabs will receive upfront product development payments of $1.65 million. Zhejiang Hisun will be responsible for all development and regulatory approval efforts for Protectan CBLB612 in China. In addition, Zhejiang Hisun will pay Cleveland BioLabs a 10% royalty on net sales over the 20-year term of the agreement. This royalty may decrease to 5% of net sales only in the event that patents for CBLB612 are not granted. Cleveland BioLabs will retain all rights to CBLB612 in the rest of the world.
Cleveland BioLabs, Inc. Receives First U.S. Patent Allowance For Its Radiation Protection Drug Protectan CBLB502
Cleveland BioLabs, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S. Patent Application Number 11/421,918, titled "Modulating Apoptosis." Allowed claims cover the method of protecting a mammal from radiation using flagellin or its derivatives, including Protectan CBLB502.
